share_log

济川药业(600566.SH):盐酸非索非那定干混悬剂获得药品注册证书

Jichuan Pharmaceutical (600566.SH): Fexofenadine hydrochloride dry suspension obtained drug registration certificate

Gelonghui Finance ·  Jun 19 06:33

On June 19th, Ge Long Hui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd (referred to as Jumpcan Limited), has received the Drug Registration Certificate for the Hydrochloride Fexofenadine Hydrochloride Dry Suspension, approved and issued by the National Medical Products Administration. Hydrochloride fexofenadine hydrochloride is a second-generation H1 receptor antagonist that can selectively block H1 receptors. It is the main active metabolite of terfenadine and has anti-histamine activity.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment